Respa-AR Interactions
There are 555 drugs known to interact with Respa-AR (atropine / chlorpheniramine / hyoscyamine / pseudoephedrine / scopolamine), along with 29 disease interactions, and 5 alcohol/food interactions. Of the total drug interactions, 32 are major, 499 are moderate, and 24 are minor.
- View all 555 medications that may interact with Respa-AR
- View Respa-AR alcohol/food interactions (5)
- View Respa-AR disease interactions (29)
Most frequently checked interactions
View interaction reports for Respa-AR (atropine / chlorpheniramine / hyoscyamine / pseudoephedrine / scopolamine) and the medicines listed below.
- amitriptyline
- Ativan (lorazepam)
- BuSpar (buspirone)
- Cardizem LA (diltiazem)
- Coreg (carvedilol)
- Diovan HCT (hydrochlorothiazide / valsartan)
- Estrace (estradiol)
- folic acid
- Glucophage XR (metformin)
- ibuprofen
- Ibuprofen PMR (ibuprofen)
- levothyroxine
- Lipitor (atorvastatin)
- Lyrica (pregabalin)
- naproxen
- Nexium (esomeprazole)
- Paxil (paroxetine)
- Reglan (metoclopramide)
- Vistaril (hydroxyzine)
- Xanax (alprazolam)
- Zanaflex (tizanidine)
Respa-AR alcohol/food interactions
There are 5 alcohol/food interactions with Respa-AR (atropine / chlorpheniramine / hyoscyamine / pseudoephedrine / scopolamine).
Respa-AR disease interactions
There are 29 disease interactions with Respa-AR (atropine / chlorpheniramine / hyoscyamine / pseudoephedrine / scopolamine) which include:
- autonomic neuropathy
- GI obstruction
- glaucoma
- obstructive uropathy
- reactive airway diseases
- myasthenia gravis
- infectious diarrhea
- cardiovascular disease
- cardiac disease
- tachycardia
- anticholinergic effects
- asthma/COPD
- cardiovascular
- renal/liver disease
- coronary artery disease
- gastric ulcer
- gastroesophageal reflux
- ulcerative colitis
- liver disease
- renal failure
- GI narrowing
- PKU
- BPH
- diabetes
- glaucoma
- hypertension
- hyperthyroidism
- diarrhea
- fever
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.